Home
report store
cutaneous t cell lymphoma ctcl epidemiology forecast

cutaneous-t-cell-lymphoma-ctcl-epidemiology-forecast-report

Cutaneous T-Cell Lymphoma(CTCL) - Epidemiology Forecast - 2034

Published Date : 2025

Pages : 105

Region : United States, Japan, EU4 & UK

Summary
TOC Table of Content
LOT
- Sample Request

cutaneous t cell lymphoma ctcl epidemiology forecast

Key Highlights

CTCLs are a heterogeneous subset of extranodal non-Hodgkin lymphomas (NHL) of mature, skin-homing T-cells that are mainly localized to the skin. The most common types of CTCL are mycosis fungoides and primary cutaneous CD30+ anaplastic large cell lymphoma (pcALCL), jointly representing an estimated 80–85% of all CTCL.
About 60% of patients are diagnosed at early stages (IA/IB), which are typically indolent with near-normal life expectancy. However, ~30% may progress to advanced-stage disease, significantly worsening prognosis.
Mycosis fungoides is the most common CTCL subtype followed by CD30+ lymphoproliferative disorders (LPD).
Although indolent in most, one-third of patients with early-stage mycosis fungoides can progress to advanced-stage disease (=IIB), with a low overall survival rate.
Currently, there are no molecular/biological markers available to predict which patients with early-stage CTCL will progress or which patients with advanced disease will enjoy a longer-than-expected life.

DelveInsight’s “Cutaneous T-cell Lymphoma (CTCL) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of CTCL, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Geography Covered

The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan

Study Period: 2020–2034

Cutaneous T-cell Lymphoma (CTCL) Understanding

Cutaneous T-cell Lymphoma (CTCL) Overview

CTCL is a type of NHL that originates in the skin, specifically from T lymphocytes, which are a subtype of white blood cells involved in immune responses to viruses and cancers. Unlike lymphomas that begin in other parts of the lymphatic system, such as the lymph nodes or organs, CTCL originates in the skin, the largest lymphoid organ in the human body. While B-cell lymphomas are more common overall, T-cell lymphomas, including CTCL, are more prevalent in the skin. CTCL is a complex and evolving condition, with numerous subtypes characterized by different growth patterns and biology. The classification of CTCL depend on the specific subtype and the underlying T-cell characteristics. Proper diagnosis and identification of the subtype are crucial as each subtype may respond differently to therapies.

Cutaneous T-cell Lymphoma (CTCL) Diagnosis

The diagnosis of CTCL is based upon a thorough clinical evaluation, detection of certain symptoms and physical findings, a detailed patient history, and various specialized tests. Such testing is necessary to confirm the specific type (and subtype) of CTCL, assess the nature and extent of the disease, and determine the most appropriate treatments. Biopsies of skin lesions are commonly performed to confirm the diagnosis, as early-stage CTCL can resemble other skin conditions like psoriasis. Multiple biopsies may be required due to the difficulty in distinguishing CTCL in its early stages. T-cell Receptor Gene Rearrangement Analysis (TCRGR) is also used to identify characteristic gene changes in T-cells. Blood tests assess white blood cell counts, liver enzymes, and Lactate Dehydrogenase (LDH) levels, with high LDH suggesting more aggressive disease. Imaging procedures such as X-rays and CT scans help determine the extent of disease spread, while a bone marrow biopsy may be conducted to check for involvement of the bone marrow. Additional tests may be needed to assess organ function, especially in cases where treatment may impact the heart or lungs.

Further details related to diagnosis will be provided in the report…

Cutaneous T-cell Lymphoma (CTCL) Epidemiology

The Cutaneous T-cell Lymphoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented total incident population, type-specific cases, gender-specific cases, stage-specific cases, treatment-eligible incident population in early and advanced stages of CTCL in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2020 to 2034.

Among the 7MM, the US accounted for the highest number of cases of CTCL in 2024, with nearly 3,000 cases. These cases are anticipated to increase by 2034.
Males accounted for the higher number of incident population of CTCL with around 60% of the total incident cases in the United States.
In the United States, among type-specific cases of CTCL in 2024, most of the cases were found to be mycosis fungoides.
Among the EU4 and the UK, Germany accounted for the highest number of ~760 cases among the total incident cases of CTCL in 2024.
Among the stage-specific incident cases of CTCL, Stage-IB accounted for the major contribution.

Cutaneous T-cell Lymphoma (CTCL) Report Insights

Cutaneous T-cell Lymphoma (CTCL) Report Insights
Patient population
Country-wise epidemiology distribution

Cutaneous T-cell Lymphoma (CTCL) Report Key Strengths

Ten-year forecast
7MM coverage
CTCL epidemiology segmentation

FAQs

What are the disease risks, burdens, and unmet needs of CTCL? What will be the growth opportunities across the 7MM concerning the patient population with CTCL?
What is the historical and forecasted CTCL patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Which gender has a higher incidence of CTCL?
Which stage of CTCL has a high patient share?
What are the most prevalent subtypes of CTCL reported under type-specific cases?

Reasons to Buy

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the recurrent and treatment-eligible patient pool.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Epidemiology Forecast Methodology

5. Disease Background and Overview

5.1. Introduction

5.2. Classification

5.2.1. Mycosis Fungoides

5.2.1.1. Variants of Mycosis Fungoides

5.2.2. Sezary Syndrome

5.2.3. Primary Cutaneous CD30-positive T-cell Lymphoproliferative Disorders (LPD)

5.3. Symptoms

5.4. Stages of CTCL

5.5. Molecular Pathogenesis

5.5.1. Immune Defects in TCL: Th2-biased Tumor Micro Environment (TME)

5.5.1.1. Role of Cytokines in Immune Dysfunction and Disease Progression in CTCL

5.5.1.2. Role of Pro-inflammatory Cytokines in CTCL

5.5.1.3. Role of Chemokines in Th1/Th2 Transition and Immune Cell Trafficking in CTCL

5.5.1.4. Role of Chemokines in Malignant T-cell Trafficking in CTCL

5.5.2. Dysregulated Signaling Pathways in CTCL

5.5.2.1. JAK/STAT Pathway and CTCL

5.5.2.2. PI3K/mTOR-signaling Pathway and CTCL

5.5.2.3. NF-?B Pathway and CTCL

5.5.2.4. MAPK Cascade and CTCL

5.6. Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Assumptions and Rationale

6.3. Total Incident Cases of CTCL in the 7MM

6.4. The United States

6.4.1. Total Incident Cases of CTCL in the United States

6.4.2. Type-specific Cases of CTCL in the United States

6.4.3. Gender-specific Cases of CTCL in the United States

6.4.4. Stage-specific Cases of CTCL in the United States

6.4.5. Treatment-eligible Pool for Early and Advanced Stages in the United States

6.5. EU4 and the UK

6.5.1. Total Incident Cases of CTCL in EU4 and the UK

6.5.2. Type-specific Cases of CTCL in EU4 and the UK

6.5.3. Gender-specific Cases of CTCL in EU4 and the UK

6.5.4. Stage-specific Cases of CTCL in EU4 and the UK

6.5.5. Treatment-eligible Pool for Early and Advanced Stages in EU4 and the UK

6.6. Japan

6.6.1. Total Incident Cases of CTCL in Japan

6.6.2. Type-specific Cases of CTCL in Japan

6.6.3. Gender-specific Cases of CTCL in Japan

6.6.4. Stage-specific Cases of CTCL in Japan

6.6.5. Treatment-eligible Pool for Early and Advanced Stages in Japan

7. Appendix

7.1. Bibliography

7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Tables:

List of Table

Table 1: Summary of CTCL Epidemiology (2020–2034)

Table 2: Lymphomatoid Papulosis: Histologic Subtypes and Differential Diagnosis

Table 3: TMNB Classification for Mycosis Fungoides and Sézary Syndrome

Table 4: Total Incident Cases of CTCL in the 7MM (2020–2034)

Table 5: Total Incident Cases of CTCL in the US (2020–2034)

Table 6: Type-specific Cases of CTCL in the US (2020–2034)

Table 7: Gender-specific CTCL Cases in the US (2020–2034)

Table 8: Stage-specific Cases of CTCL in the US (2020–2034)

Table 9: Treatment-eligible Pool for Early and Advanced Stages in the US (2020–2034)

Table 10: Total Incident Cases of CTCL in EU4 and the UK (2020–2034)

Table 11: Type-specific Cases of CTCL in EU4 and the UK (2020–2034)

Table 12: Gender-specific Cases of CTCL in EU4 and the UK (2020–2034)

Table 13: Stage-specific Cases of CTCL in EU4 and the UK (2020–2034)

Table 14: Treatment-eligible Pool for Early and Advanced Stages in EU4 and the UK (2020–2034)

Table 15: Total Incident Cases of CTCL in Japan (2020–2034)

Table 16: Type-specific Cases of CTCL in Japan (2020–2034)

Table 17: Gender-specific CTCL Cases in Japan (2020–2034)

Table 18: Stage-specific Cases of CTCL in Japan (2020–2034)

Table 19: Treatment-eligible Pool for Early and Advanced Stages in Japan (2020–2034)

List of Figures:

List of Figures

Figure 1: Role of Cytokines in the Development of a Th2-biased Inflammatory Milieu Through the Modulation of Chemokines

Figure 2: Spectrum of Recurrently Mutated Signaling Pathways in CTCL

Figure 3: Total Incident Cases of CTCL in the 7MM (2020–2034)

Figure 4: Total Incident Cases of CTCL in the US (2020–2034)

Figure 5: Type-specific Cases of CTCL in the US (2020–2034)

Figure 6: Gender-specific CTCL Cases in the US (2020–2034)

Figure 7: Stage-specific Cases of CTCL in the US (2020–2034)

Figure 8: Treatment-eligible Pool for Early and Advanced Stages in the US (2020–2034)

Figure 9: Total Incident Cases of CTCL in EU4 and the UK (2020–2034)

Figure 10: Type-specific Cases of CTCL in EU4 and the UK (2020–2034)

Figure 11: Gender-specific Cases of CTCL in EU4 and the UK (2020–2034)

Figure 12: Stage-specific Cases of CTCL in EU4 and the UK (2020–2034)

Figure 13: Treatment-eligible Pool for Early and Advanced Stages in EU4 and the UK (2020–2034)

Figure 14: Total Incident Cases of CTCL in Japan (2020–2034)

Figure 15: Type-specific Cases of CTCL in Japan (2020–2034)

Figure 16: Gender-specific CTCL Cases in Japan (2020–2034)

Figure 17: Stage-specific Cases of CTCL in Japan (2020–2034)

Figure 18: Treatment-eligible Pool for Early and Advanced Stages in Japan (2020–2034)

Figure 19: Reimbursement Process in Japan

Related Reports

Cutaneous T-Cell Lymphoma(CTCL) - Market Insight, Epidemiology and Market Forecast - 2027

DelveInsight's 'Cutaneous T-Cell Lymphoma(CTCL)- Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Cutaneous T-Cell Lymphoma(CTCL) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

License Type

Offer